Abstract The Japanese Society of Gastroenterology revised the evidence-based clinical
practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected …

Primary biliary cirrhosis (PBC) is an immune-mediated chronic cholestatic liver disease with
a slowly progressive course. Without treatment, most patients eventually develop fibrosis …

Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver
disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is …

Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an
autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury …

Background & Aims We evaluated the efficacy and safety of obeticholic acid (OCA, α-
ethylchenodeoxycholic acid) in a randomized controlled trial of patients with primary biliary …

Hong You1· Xiong Ma2· Cumali Efe3· Guiqiang Wang4· Sook‑Hyang Jeong5· Kazumichi
Abe6· Weijia Duan1· Sha Chen1· Yuanyuan Kong7· Dong Zhang8· Lai Wei9· Fu‑Sheng …

Background & Aims Noninvasive surrogate end points of long-term outcomes of patients
with primary biliary cirrhosis (PBC) are needed to monitor disease progression and evaluate …

Background & Aims The clinical efficacy of ursodeoxycholic acid (UDCA) in primary biliary
cholangitis (PBC) remains subject to debate as definitive randomized controlled trials are …

EASL Clinical Practice Guidelines (CPG) on the management of cholestatic liver diseases
define the use of diagnostic, therapeutic and preventive modalities, including non-invasive …

Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary
cirrhosis (PBC) is variable. It has been recently proposed that an alkaline phosphatase …